RxDoctor Payments DataLook up a doctor →

Jeffrey Horn, MD

Ophthalmology · Nashville, TNNPI 1134210149

Payments from drug & device makers

$1,190,820in general payments, 2019–2025

Across 1,445 payments — averaging $824.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$975K
  • Alcon$91K
  • Novartis$79K
  • Bausch & Lomb Americas Inc.$30K
  • Bausch Health US, LLC$14K
  • Carl Zeiss Meditec USA, Inc.$821
  • plus $1K from 12 others
$282,867in research payments, 2019–2025

Across 539 payments — averaging $524.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$232K
  • Bausch Health US, LLC$51K

What the payments were for

  • Consulting fees$87,70383%
  • Speaking & faculty fees$6,2246%
  • Travel & lodging$5,3535%
  • Food & beverage$6,9257%
  • Education$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,190,820 in reported general payments places this provider in the 95th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$197,326
Medicare patients
466
Services billed
1,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine12$20,899
CombiganBrimonidine Tartrate/Timolol36$13,958
ProlensaBromfenac Sodium29$9,860
LumiganBimatoprost15$9,282
BesivanceBesifloxacin Hcl38$8,269
VyzultaLatanoprostene Bunod26$7,740
InveltysLoteprednol Etabonate13$3,756
Latanoprost55$972
Prednisolone Acetate20$964
Doxycycline Hyclate27$892
Atropine Sulfate23$783
MoxifloxacinMoxifloxacin Hcl42$722
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat13$634
Dorzolamide Hcl24$603
Timolol Maleate48$429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$566$44,13963 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance$63$18,13067 claims
Bausch & Lomb Americas Inc.Vyzulta$29,557$7,74026 claims
Kala Pharmaceuticals, Inc.Inveltys$179$3,75613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →